Efficacy and Safety of Tixagevimab/Cilgavimab to Prevent COVID-19 (Pre-Exposure Prophylaxis): A Systematic Review and Meta-Analysis.

Saad AlhumaidAbbas Al MutairJalal AlaliNourah Al DossarySami Hussain AlbattatSarah Mahmoud Al HajjiMohammedFatimah Saad AlmuaiweedMaryam Radhi AlZaidMohammed Jaber AlomranZainab Sabri AlquriniAhmed Abduljalil AlsultanThamer Saeed AlhajjiSukainah Mohammad AlshaikhnasirAli Al MotaredKoblan M Al MutaredKhalid Hajissa Ali A Rabaan

Published in: Diseases (Basel, Switzerland) (2022)

For PrEP, TGM/CGM-based treatment can be associated with a better clinical outcome than no treatment or other alternative treatment. However, more randomized control trials are warranted to confirm our findings and investigate the efficacy and safety of TGM/CGM to prevent COVID-19 in patients at risk for breakthrough or severe SARS-CoV-2 infection.

Keyphrases

coronavirus disease
sars cov
end stage renal disease
chronic kidney disease
randomized controlled trial
newly diagnosed
early onset
combination therapy
peritoneal dialysis
respiratory syndrome coronavirus
replacement therapy